The male study investigators want mammography to fail so they can divert research money to prevent prostate cancer. ... I do not dispute this contention. How many men, however, were gravely harmed by treatment of prostate cancer that would have never
It's those patients with NASH that are at the greatest risk for progression to cirrhosis or liver cancer, and so those are the ones we want to identify and develop ... Drawbacks include a potential increase in all-cause mortality with vitamin E
An Annals of Internal Medicine editorial in the May 5 issue again notes that, “Within 10 years of trial entry, screening increases the number of cancer cases diagnosed but has no ... by overzealous therapies and like to pronounce themselves as
You likely know several examples of “dueling guidelines,” breast cancer screening, prostate cancer screening, and goals of diabetes control.
Start with basic internal medicine. If an older patient with metastatic hormone-refractory prostate cancer has heart failure and shortness of breath, the best palliative care may be to treat his ... For instance, the patient may have a pulmonary embolism
Many clinical questions yield “competing guidelines.” We all know the controversies over breast cancer screening and prostate cancer screening.
A few months back, The New York Times reported on two new drugs, approved by the FDA for cancer treatment. ... Provenge, a new drug for prostate cancer extends life by four months at a cost of $93,000.
For example, prostate cancer screening has been in the news lately. ... More evidence suggests that screening for prostate cancer may not only be unnecessary but also potentially harmful.
The furor over the lack of benefit for men of the screening Prostate Specific Antigen test (PSA) is still being heard. ... This is bad news because every year over 21,000 women are diagnosed with ovarian cancer.
for your prostate cancer. ... We believe that our own patient with pancreatic cancer might be the one who feels better on Gemzar.